In support of these findings, we have previously demonstrated that CSF QUIN levels in MS patients positively correlate with neurofilament light chain (NfL) levels, a well-established biomarker of neuroaxonal damage [57]. The gene discussed is NEFL; the disease is myeloid sarcoma.